PubRank

Gabriella Fontanini

Author PubWeight™ 75.99‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 ZD6474, an orally available inhibitor of KDR tyrosine kinase activity, efficiently blocks oncogenic RET kinases. Cancer Res 2002 3.33
2 Antitumor effects of ZD6474, a small molecule vascular endothelial growth factor receptor tyrosine kinase inhibitor, with additional activity against epidermal growth factor receptor tyrosine kinase. Clin Cancer Res 2003 2.26
3 Bevacizumab with FOLFOXIRI (irinotecan, oxaliplatin, fluorouracil, and folinate) as first-line treatment for metastatic colorectal cancer: a phase 2 trial. Lancet Oncol 2010 1.97
4 Advanced stage thymomas and thymic carcinomas: results of multimodality treatments. Ann Thorac Surg 2005 1.75
5 Novel pyrazolopyrimidine derivatives as tyrosine kinase inhibitors with antitumoral activity in vitro and in vivo in papillary dedifferentiated thyroid cancer. J Clin Endocrinol Metab 2010 1.68
6 Mechanical prevention of distal embolization during primary angioplasty: safety, feasibility, and impact on myocardial reperfusion. Circulation 2003 1.68
7 Combination of a selective cyclooxygenase-2 inhibitor with epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 and protein kinase A antisense causes cooperative antitumor and antiangiogenic effect. Clin Cancer Res 2003 1.55
8 Distal embolization during primary angioplasty: histopathologic features and predictability. Am Heart J 2005 1.47
9 A phase II study of intrapleural immuno-chemotherapy, pleurectomy/decortication, radiotherapy, systemic chemotherapy and long-term sub-cutaneous IL-2 in stage II-III malignant pleural mesothelioma. Eur J Cardiothorac Surg 2006 1.45
10 Enhancement of antitumor activity of ionizing radiation by combined treatment with the selective epidermal growth factor receptor-tyrosine kinase inhibitor ZD1839 (Iressa). Clin Cancer Res 2002 1.43
11 Osteopontin expression and prognostic significance in non-small cell lung cancer. Clin Cancer Res 2005 1.35
12 Expression and mutational status of c-kit in small-cell lung cancer: prognostic relevance. Clin Cancer Res 2004 1.25
13 Sleeve and wedge parenchyma-sparing bronchial resections in low-grade neoplasms of the bronchial airway. J Thorac Cardiovasc Surg 2007 1.22
14 Mutational analysis in cytological specimens of advanced lung adenocarcinoma: a sensitive method for molecular diagnosis. J Thorac Oncol 2007 1.22
15 WWOX expression in different histologic types and subtypes of non-small cell lung cancer. Clin Cancer Res 2007 1.06
16 Cooperative antitumor effect of multitargeted kinase inhibitor ZD6474 and ionizing radiation in glioblastoma. Clin Cancer Res 2005 1.04
17 Let-7g and miR-21 expression in non-small cell lung cancer: correlation with clinicopathological and molecular features. Int J Oncol 2013 1.03
18 ALK rearrangement in a large series of consecutive non-small cell lung cancers: comparison between a new immunohistochemical approach and fluorescence in situ hybridization for the screening of patients eligible for crizotinib treatment. Arch Pathol Lab Med 2014 1.03
19 Role of NRAS mutations as prognostic and predictive markers in metastatic colorectal cancer. Int J Cancer 2014 1.02
20 Recommendations for mutational analysis of EGFR in lung carcinoma. Pathologica 2010 1.00
21 Percutaneous radiofrequency ablation of lung tumours: results in the mid-term. Eur J Cardiothorac Surg 2006 1.00
22 Small cell lung carcinoma (SCLC): the angiogenic phenomenon. Eur J Cardiothorac Surg 2002 1.00
23 TLR9 agonist acts by different mechanisms synergizing with bevacizumab in sensitive and cetuximab-resistant colon cancer xenografts. Proc Natl Acad Sci U S A 2007 0.96
24 Anti-tumor activity of the combination of cetuximab, an anti-EGFR blocking monoclonal antibody and ZD6474, an inhibitor of VEGFR and EGFR tyrosine kinases. J Cell Physiol 2006 0.93
25 Inherited germline T790M mutation and somatic epidermal growth factor receptor mutations in non-small cell lung cancer patients. J Thorac Oncol 2011 0.93
26 Thymidylate synthase, dihydropyrimidine dehydrogenase and thymidine phosphorylase expression in colorectal cancer and normal mucosa in patients. Pharmacogenet Genomics 2006 0.93
27 Radiofrequency ablation of lung malignancies: where do we stand? Cardiovasc Intervent Radiol 2004 0.93
28 Epidermal growth factor receptor and K-RAS mutations in 411 lung adenocarcinoma: a population-based prospective study. Oncol Rep 2009 0.93
29 Malignancies within rhinophyma: report of three new cases and review of the literature. Aesthetic Plast Surg 2011 0.92
30 Anaplastic lymphoma kinase gene rearrangements in cytological samples of non-small cell lung cancer: comparison with histological assessment. Cancer Cytopathol 2014 0.90
31 Thermal ablation of lung tissue: in vivo experimental comparison of microwave and radiofrequency. Cardiovasc Intervent Radiol 2010 0.89
32 Expression of p-AKT and p-mTOR in a large series of bronchopulmonary neuroendocrine tumors. Exp Ther Med 2011 0.88
33 An "inflammatory" mitochondrial myopathy. A case report. Neuromuscul Disord 2013 0.88
34 EGFR ligands as pharmacodynamic biomarkers in metastatic colorectal cancer patients treated with cetuximab and irinotecan. Target Oncol 2013 0.88
35 Expression of endothelin-1 is related to poor prognosis in non-small cell lung carcinoma. Eur J Cancer 2005 0.88
36 DeltaN133p53 expression levels in relation to haplotypes of the TP53 internal promoter region. Hum Mutat 2010 0.88
37 BRAF status of follicular variant of papillary thyroid carcinoma and its relationship to its clinical and cytological features. Thyroid 2010 0.87
38 Biologic effects of radiofrequency thermal ablation on non-small cell lung cancer: results of a pilot study. J Thorac Cardiovasc Surg 2006 0.86
39 Interleukin-8 in non-small cell lung carcinoma: relation with angiogenic pattern and p53 alterations. Lung Cancer 2005 0.86
40 Glomus tumor of the shoulder: A case report and review of the literature. Oncol Lett 2013 0.86
41 Different estrogen receptor beta expression in distinct histologic subtypes of lung adenocarcinoma. Hum Pathol 2008 0.86
42 Galectin-3 and oncofetal-fibronectin expression in thyroid neoplasia as assessed by reverse transcription-polymerase chain reaction and immunochemistry in cytologic and pathologic specimens. Thyroid 2003 0.85
43 CD34 microvessel density and VEGF expression in basal and squamous cell carcinoma. Pathol Res Pract 2003 0.85
44 Four-modality therapy in malignant pleural mesothelioma: a phase II study. J Thorac Oncol 2007 0.85
45 Beyond KRAS: perspectives on new potential markers of intrinsic and acquired resistance to epidermal growth factor receptor inhibitors in metastatic colorectal cancer. Ther Adv Med Oncol 2009 0.84
46 Tryptase mast cells in malignant pleural mesothelioma as an independent favorable prognostic factor. J Thorac Oncol 2009 0.83
47 CLM3, a multitarget tyrosine kinase inhibitor with antiangiogenic properties, is active against primary anaplastic thyroid cancer in vitro and in vivo. J Clin Endocrinol Metab 2014 0.83
48 Intraoperative sentinel lymph node mapping in stage I non-small cell lung cancer: detection of micrometastases by polymerase chain reaction. Eur J Cardiothorac Surg 2008 0.83
49 EGFR and K-Ras mutations in women with lung adenocarcinoma: implications for treatment strategy definition. J Exp Clin Cancer Res 2014 0.83
50 Metronomic 5-fluorouracil, oxaliplatin and irinotecan in colorectal cancer. Eur J Pharmacol 2009 0.83
51 CLM94, a novel cyclic amide with anti-VEGFR-2 and antiangiogenic properties, is active against primary anaplastic thyroid cancer in vitro and in vivo. J Clin Endocrinol Metab 2012 0.82
52 Effect of the p53 codon 72 and intron 3 polymorphisms on non-small cell lung cancer (NSCLC) prognosis. Cancer Invest 2008 0.82
53 Antitumor activity of ZD6474, a vascular endothelial growth factor-2 and epidermal growth factor receptor small molecule tyrosine kinase inhibitor, in combination with SC-236, a cyclooxygenase-2 inhibitor. Clin Cancer Res 2005 0.82
54 Tumour necrosis factor-alpha: prognostic role and relationship with interleukin-8 and endothelin-1 in non-small cell lung cancer. Int J Mol Med 2006 0.82
55 Irinotecan synergistically enhances the antiproliferative and proapoptotic effects of axitinib in vitro and improves its anticancer activity in vivo. Neoplasia 2011 0.81
56 Advanced non-small cell lung cancer management in patients progressing after first-line treatment: results of the cross-sectional phase of the Italian LIFE observational study. J Cancer Res Clin Oncol 2014 0.81
57 MERRF syndrome without ragged-red fibers: the need for molecular diagnosis. Biochem Biophys Res Commun 2007 0.81
58 Multimodality treatment of malignant pleural mesothelioma with or without immunotherapy: does it change anything? Interact Cardiovasc Thorac Surg 2010 0.80
59 p95HER2 truncated form in resected non-small cell lung cancer. J Thorac Oncol 2012 0.80
60 Expression of cyclooxygenase-2 and its correlation with vasogenic brain edema in human intracranial meningiomas. Cancer Invest 2007 0.80
61 Coexistence of TERT promoter and BRAF mutations in cutaneous melanoma is associated with more clinicopathological features of aggressiveness. Virchows Arch 2015 0.80
62 EML4-ALK translocation in both metachronous second primary lung sarcomatoid carcinoma and lung adenocarcinoma: a case report. Lung Cancer 2013 0.80
63 Phosphatidylinositol-3-kinase α catalytic subunit gene somatic mutations in bronchopulmonary neuroendocrine tumours. Oncol Rep 2012 0.80
64 CDC25B: relationship with angiogenesis and prognosis in non-small cell lung carcinoma. Hum Pathol 2007 0.80
65 Regulation of telomerase and its hTERT messenger in colorectal cancer. Oncol Rep 2004 0.80
66 Prognostic impact of p53 Pro72 homozygous genotype in non-small cell lung cancer patients. Oncol Rep 2008 0.80
67 Meningeal hemangiopericytoma metastatic to the adrenal gland with multiple metastases to bones and lungs: a case report. Tumori 2004 0.79
68 Antiproliferative and proapoptotic activity of sunitinib on endothelial and anaplastic thyroid cancer cells via inhibition of Akt and ERK1/2 phosphorylation and by down-regulation of cyclin-D1. J Clin Endocrinol Metab 2013 0.79
69 Applications of tissue microarray technology in immunohistochemistry: a study on c-kit expression in small cell lung cancer. Hum Pathol 2004 0.77
70 Benefit from a high dose of gefitinib in a woman with lung adenocarcinoma and an epidermal growth factor receptor tyrosine-kinase acquired mutation. Mol Med Rep 2011 0.77
71 The administration of gefitinib in patients with advanced non-small-cell lung cancer after the failure of erlotinib. Cancer Chemother Pharmacol 2012 0.77
72 P2X7 protein expression and polymorphism in non-small cell lung cancer (NSCLC). J Negat Results Biomed 2014 0.77
73 Differential expression of extracellular matrix constituents and cell adhesion molecules between malignant pleural mesothelioma and mesothelial hyperplasia. J Thorac Oncol 2013 0.77
74 CXC chemokine receptor 4 immunodetection in the follicular variant of papillary thyroid carcinoma: comparison to galectin-3 and hector battifora mesothelial cell-1. Thyroid 2010 0.77
75 Expression of endothelin 1 and its angiogenic role in meningiomas. Virchows Arch 2006 0.77
76 Immunohistochemical and molecular study of radiation-induced multiple meningiomas with pleural and pulmonary metastasis. Tumori 2004 0.76
77 KIF5B/RET fusion gene analysis in a selected series of cytological specimens of EGFR, KRAS and EML4-ALK wild-type adenocarcinomas of the lung. Lung Cancer 2013 0.76
78 Mutations of Fas (APO-1/CD95) and p53 genes in nonmelanoma skin cancer. J Cutan Med Surg 2002 0.75
79 Clear cell adenocarcinoma of the base of the tongue: a case report and review of the literature. Ear Nose Throat J 2011 0.75
80 Discordant somatic and germline VEGF-A genotype in a cancer patient resistant to paclitaxel/bevacizumab with chemosensitive hepatic metastasis. Pharmacogenomics 2009 0.75
81 Advances in molecular diagnostics for mitochondrial diseases. Expert Opin Med Diagn 2009 0.75
82 Novel Pyrazolopyrimidine Derivatives as Tyrosine Kinase Inhibitors with Antitumoral Activity in Vitro and in Vivo in Papillary Dedifferentiated Thyroid Cancer. Endocrinology 2011 0.75
83 Distal embolization during angioplasty for acute myocardial infarction: is pharmacological protection enough? Thromb Haemost 2005 0.75
84 Novel MTCYB mutation in a young patient with recurrent stroke-like episodes and status epilepticus. Am J Med Genet A 2014 0.75
85 Laser capture microdissection: a tool for the molecular characterization of histologic subtypes of lung adenocarcinoma. Int J Mol Med 2009 0.75
86 The role of somatostatin in vasogenic meningioma associated brain edema. Tumori 2003 0.75